REGION VI RCE - NONHUMAN PRIMATE CORE

第六区 RCE - 非人类灵长类核心

• 批准号: 7562433
• 负责人: DAVID H WALKER
• 金额: $ 14.5万
• 依托单位: TEXAS BIOMEDICAL RESEARCH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-05-01 至 2008-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7562433
• 关键词: Animal Welfare; Animals; Arkansas; Arts; Biology; Bioterrorism; Caring; Categories; Class; Clinical Pathology; Clinical Sciences; Collaborations; Computational Biology; Computer Retrieval of Information on Scientific Projects Database; Condition; Consensus; Creativeness; Development; Diagnostic; Emerging Communicable Diseases; Ensure; Funding; Generations; Genomics; Grant; Human; Human Resources; Institution; Laboratories; Louisiana; Mission; National Institute of Allergy and Infectious Disease; New Mexico; Oklahoma; Pharmaceutical Preparations; Population; Primates; Process; Production; Proteomics; Regulation; Research; Research Infrastructure; Research Personnel; Research Project Grants; Resources; Source; Testing; Texas; Therapeutic; Training; United States Food and Drug Administration; United States National Institutes of Health; base; biodefense; biothreat; design; infectious disease model; innovation; laboratory facility; nonhuman primate; novel diagnostics; novel vaccines; pathogen; programs; research and development; research study; response; scale up; therapeutic vaccine; vaccine development

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. In response to NIAID's call for the creation of strong infrastructure and multifaceted research and development activities applying the best basic, translational, and clinical science to the generation of new diagnostic, therapeutic and vaccine countermeasures for Category A, B, and C pathogens posing threats as agents of bioterrorism, 22 institutions in Texas, New Mexico, Oklahoma, Arkansas, and Louisiana have combined their energy, creativity, and resources to create the Western (Region Vl) Center of Excellence for Biodefense and Emerging Infectious Diseases (WRCE). Nine scientific cores will provide access to state-of-the-art proteomics, genomics, standardized small animal and non-human primate models of infectious diseases, BSL-4 laboratory facilities, and GLP scale-up production, as well as crosscutting functions in computational biology and a streamlined process for translational development of vaccines and drugs leading to FDA approval. A consistently strong spirit of cooperation among traditionally competing institutions has established an interlocking network of projects, cores, and administration that will strengthen and flourish as the Center is implemented. The guidance of this network of interactive research projects and core resource facilities will be executed under a comprehensive administrative plan to contribute substantially to the nation's biodefense mission by fulfilling a carefully crafted scientific strategy on a common theme; Collaborations for host-pathogen biology based development of novel vaccines, diagnostics, and therapeutics against biothreat agents. There is a clear consensus that nonhuman primates will be a necessary part of the development of therapeutics and vaccines for the NIAID Class A and Class B agents. For many of these agents, human trials will be very limited or impossible. In addition, appropriate animal BL3 facilities and personnel trained in the handling of primates under BL3 and perhaps BL4 conditions will be necessary in order to ensure efficient and timely transfer of advances in therapeutics and vaccines to the human population. The NHP Core of the RCE will: 1. provide oversight and assistance in the acquisition of animals by investigators using nonhuman primates in this proposal and assure compliance with federal animal welfare and biosafety regulations; 2. provide for the routine veterinary care and husbandry for nonhuman primates assigned to projects contained within this program; 3. provide expertise and assistance in the design and implementation of experiments using nonhuman primates; 4. provide for clinical and pathology laboratory support for studies using nonhuman primates; 5. develop new and innovative nonhuman primate resources for use in testing therapeutics and vaccines.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 In response to NIAID's call for the creation of strong infrastructure and multifaceted research and development activities applying the best basic, translational, and clinical science to the generation of new diagnostic, therapeutic and vaccine countermeasures for Category A, B, and C pathogens posing threats as agents of bioterrorism, 22 institutions in Texas, New Mexico, Oklahoma, Arkansas, and Louisiana have结合了他们的能量，创造力和资源，以创建西方（区域VL）生物化和新兴传染病（WRCE）的卓越中心。九个科学核心将提供最先进的蛋白质组学，基因组学，标准化的小动物和非人类灵长类动物模型的传染病模型，BSL-4实验室设施以及GLP扩展生产，以及在计算生物学中的跨缩合功能，以及用于转化疫苗和药物批准的流线发展过程。传统上竞争的机构之间始终如一的强烈合作精神建立了一个互锁的项目，核心和管理网络，随着中心的实施，将加强和繁荣。该互动研究项目和核心资源设施网络的指导将在一项全面的行政计划下执行，以实现对共同主题精心制作的科学策略，从而为该国的Biodefense任务做出基本贡献；针对生物治疗剂的新型疫苗，诊断和治疗剂的基于宿主生物生物学的合作。 明确的共识是，非人类灵长类动物将是NIAID A类和B类代理的疗法和疫苗开发的必要组成部分。对于许多这些代理商，人类试验将非常有限或不可能。此外，为了确保将治疗剂和疫苗进步的效率和及时转移到人口中，需要在BL3下处理灵长类动物的适当动物BL3设施和人员。 RCE的NHP核心将：1。在该提案中使用非人类灵长类动物的调查人员获得动物的监督和协助，并确保遵守联邦动物福利和生物安全法规； 2。为分配给本计划中包含的项目的非人类灵长类动物提供常规兽医护理和饲养； 3。在使用非人类灵长类动物的实验设计和实施方面提供专业知识和帮助； 4。为使用非人类灵长类动物的研究提供临床和病理实验室支持； 5。开发新的和创新的非人类灵长类动物资源，用于测试治疗剂和疫苗。